Strategic positioning Private biotech with a focus on premium antibodies and monoclonal antibody platforms, positioned in the Greater Boston biopharma hub. Potential sales opportunities with IVD manufacturers and academic researchers seeking high-affinity antibodies and customized services.

Acquisition heritage Previously acquired by ABclonal Science, indicating established corporate backing and integration potential. Leverage this affinity with ABclonal’s broader distribution and partner networks to expand offerings and co-sell antibody services.

Monoclonal strength Specialization in rabbit monoclonal antibodies and a single-B-cell SMab platform with high screening efficiency. Target collaborators in diagnostics, research labs, and biotech tool providers needing rapid, high-affinity mAbs.

Service diversification Custom antibody development and distribution of a growing catalog of antibodies for research and IVD applications. Upsell opportunities for tailored antibody production, validation services, and volume/lab-scale packages.

Commercial maturity Revenue range indicates a mature small-to-mid biotech revenue stream with room to scale. Focus on expanding client footprints in pharma tools, contract research, and academic sectors through bundled offerings and co-development deals.